Omega-3作为抗抑郁增效剂治疗抑郁症的疗效及其免疫机制

注册号:

Registration number:

ChiCTR-IPC-15006700 

最近更新日期:

Date of Last Refreshed on:

2015-07-06 18:03:58 

注册时间:

Date of Registration:

2015-07-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

Omega-3作为抗抑郁增效剂治疗抑郁症的疗效及其免疫机制

Public title:

Efficacy and immune mechanisms of omega-3 as synergist in treatment of major depressive disorder

注册题目简写:

English Acronym:

研究课题的正式科学名称:

功能食品及免疫调节干预调理抑郁症

Scientific title:

Functional foods and immunomodulatory in intervention of major depressive disorder

研究课题代号(代码):

Study subject ID:

广州市医学重点学科(GBH2014-ZD08)

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

林鄞 

研究负责人:

曹莉萍 

Applicant:

Yin Lin 

Study leader:

Liping Cao 

申请注册联系人电话:

Applicant telephone:

+86 15817176514

研究负责人电话:

Study leader's
telephone:

+86 20 81123695

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

linymn@163.com

研究负责人电子邮件:

Study leader's E-mail:

coolliping@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市荔湾区明心路36号

研究负责人通讯地址:

广东省广州市荔湾区明心路36号

Applicant address:

36 Mingxin Road, Liwan District, Guangzhou, Guangdong

Study leader's address:

36 Mingxin Road, Liwan District, Guangzhou, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州市惠爱医院

Applicant's institution:

Guangzhou Huiai Hospital

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2015)第(032)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广州市惠爱医院伦理委员会

Name of the ethic committee:

Ethic committee of Guangzhou Huiai Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2015-06-23 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广州市惠爱医院

Primary sponsor:

Guangzhou Huiai Hospital

研究实施负责(组长)单位地址:

广东省广州市荔湾区明心路36号

Primary sponsor's address:

36 Mingxin Road, Liwan District, Guangzhou, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

China

Province:

Guangdong

City:

Guangzhou City

单位(医院):

广州市惠爱医院

具体地址:

广东省广州市荔湾区明心路36号

Institution
hospital:

Guangzhou Huiai Hospital

Address:

36 Mingxin Road, Liwan District, Guangzhou, Guangdong

经费或物资来源:

广州市医学重点学科(GBH2014-ZD08)

Source(s) of funding:

Guangzhou key medical disciplines (GBH2014-ZD08)

研究疾病:

抑郁症  

Target disease:

Major depressive disorder

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

1. Omega-3合并抗抑郁药治疗抑郁症的临床疗效。 2. 从细胞因子和肠道菌群DNA的改变,进一步探讨omega-3抗抑郁的免疫机制。  

Objectives of Study:

1. Efficacy of omega-3 combined with antidepressants in treatment of major depressive disorder; 2. Expolore immune mechanism of omega-3 in treatment of depression by examing cell factors and DNA of intestinal microflora.

药物成份或治疗方案详述:

抗抑郁药物;omega-3 

Description for medicine or protocol of treatment in detail:

Antidepressants;omega-3 

纳入标准:

Inclusion criteria

排除标准:

①双相抑郁,躯体疾病伴发的抑郁,物质滥用或依赖所致的抑郁;
②既往使用过毒品或有精神活性物质依赖,或其他精神障碍;
③神经系统疾病;
④明显的躯体疾病;
⑤处于妊娠期和哺乳期的妇女;
⑥需行MECT者。

Exclusion criteria:

1. Bipolar depression, or depression associated with physical illness or caused by substance abuse or dependence;
2. Previously drugs used or psychoactive substance dependence, or other mental disorders;
3. Nervous system diseases;
4. Obvious physical diseases;
5. In pregnant or lactating;
6. Needed treatment of MECT.

研究实施时间:

Study execute time:

From 2015-06-01 00:00:00 To 2017-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2015-07-20 00:00:00 To 2016-12-23 00:00:00

干预措施:

Interventions:

组别:

A

样本量:

40

Group:

A

Sample size:

干预措施:

抗抑郁药 + Omega-3

干预措施代码:

Intervention:

Antidepressants + Omega-3

Intervention code:

组别:

B

样本量:

40

Group:

B

Sample size:

干预措施:

抗抑郁药

干预措施代码:

Intervention:

Antidepressants

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

广州市 

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州市惠爱医院 

单位级别:

三级甲等 

Institution
hospital:

Guangzhou Huiai Hospital

Level of the institution:

Tertiary Hospital

测量指标:

Outcomes:

指标中文名:

汉密尔顿抑郁量表-17项

指标类型:

主要指标

Outcome:

Hamilton ratin scale for depression (17-items)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

外周静脉

Sample Name:

Blood

Tissue:

Peripheral vein

人体标本去向

使用后销毁  

说明

检测细胞因子

Fate of sample:

Destruction after use  

Note:

Examine cell factors

标本中文名:

粪便

组织:

Sample Name:

Excrement

Tissue:

人体标本去向

使用后销毁  

说明

提取细菌DNA进行检测

Fate of sample:

Destruction after use  

Note:

Examine DNA of bacterium

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age 45 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

由不参与样本收集及评估的研究人员,采用随机数字表,将入组对象随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

The subjects are randomly assigned to different groups by researchers not involved in the collection or evaluation, using random number table.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2015-07-06 18:03:58